Adeno-associated viral (AAV) vectors have emerged as the leading gene delivery platform for gene therapy. Capsid proteins play an important role in cell binding, internalization, and trafficking, ...

Voyager is leading the development of next-generation AAV capsids—which are the outer viral protein shells that ... s mission is its trademark AAV capsid-discovery platform, Tropism Redirection ...

The empty-to-full capsid ratio ... DNA and protein in a single well using the unmatched precision of Droplet DigitalTM PCR (ddPCR). The entire adeno-associated virus (AAV) production workflow ...

Many pathogenic viruses require a specific structure ... capsid. For many viruses, however, subunit-subunit binding interfaces show little variation between different conformations in the crystal ...

Latus’ other lead gene therapy uses its AAV-Ep+ capsid to target ependymal cells as well as neurons. Ependymal cells secrete proteins into the cerebrospinal fluid. Co-opting this function ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.

and then modified an AAV capsid to specifically target this receptor. To achieve this, the team has developed a new methodology using artificial intelligence tools, based on protein structure ...

There are many different types of AAV capsids—the protein shells of virus particles ... examining the effects of various delivery routes. One capsid, AAV-KP1, stood out as particularly effective ...

While naturally occurring AAV capsids lack precise targeting to ... by generating high-performance out-of-distribution capsid proteins. About Dyno Therapeutics Dyno Therapeutics is building ...